Special Issue

Metabolomic Studies in Metabolic Diseases

Message from the Guest Editor

Obesity, diabetes and cardiovascular disease are part of a disease continuum involving metabolic dysregulation. These metabolic diseases represent a growing health burden on most countries and are the focus of much research. Metabolomic studies have the potential to inform on the altered metabolism preceding, or resulting from, these chronic diseases. Such studies can provide insight into the pathogenesis of disease, identify new biomarkers for disease risk stratification and/or new therapeutic targets. Here we call for manuscripts addressing all aspects of metabolomic studies into these chronic metabolic diseases.


Guest Editor

Prof. Dr. Peter Meikle

Metabolomics Laboratory NHMRC, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia

Deadline for manuscript submissions

closed (30 March 2017)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/3721

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

